ALAN H. AUERBACH - 12 Feb 2024 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
Issuer symbol
PBYI
Transactions as of
12 Feb 2024
Net transactions value
$0
Form type
4
Filing time
14 Feb 2024, 17:58:48 UTC
Previous filing
05 Jan 2024
Next filing
19 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Award $0 +160,796 +2.3% $0.000000 7,097,743 12 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBYI Stock Option (Right to Buy) Award $0 +222,573 $0.000000 222,573 12 Feb 2024 Common Stock 222,573 $6.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events.
F2 Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events.